Live flu vaccine trial

By Kate McDonald
Friday, 27 February, 2009

Melbourne’s BioDiem and Schering-Plough’s vaccine business unit Nobilon have begun a clinical development program for BioDiem’s intranasal live attenuated influenza vaccine (LAIV).

The vaccine, named SCH 900795, is composed of three attenuated flu viruses that will be delivered in a single-dose intranasal spray.

The Phase I study will test the safety, tolerability and immunogenicity of the vaccine in 120 healthy volunteers.

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Content from other channels on our network

Burnet, Atomo to jointly develop active syphilis self-test

My Health Record: ADHA seeks industry input on support, maintenance

Monash, Optiscan partner to develop AI-powered endoscopes

Review proposes major health system changes

Private Health CEO Forum to tackle financial viability issues

Custom Denning achieves first pantograph fast-charging electric bus

Orica cuts particle emissions from Kooragang Island site by 95%

Air-gapped networks give a false sense of security

BHP strengthens partnership with ABB

Seamless modular I/O integration

SA project uses Cement Australia's low-carbon tech

Data centres working to use water responsibly

Orica cuts particle emissions from Kooragang Island site by around 95%

CSIRO's new facility for printed flexible solar techology

Driving change: how electric vehicles are fuelling Australia's sustainable businesses